Drug Trial Radar · NCT07141199
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 2, 2025
Primary completion
Mar 23, 2026
Study completion Mar 23, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-8736Drug
Intravenous (IV) Infusion
PlaceboDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 113 Days
- Maximum Observed Concentration (Cmax) of ABBV-8736Time frame: Up to Approximately 113 Days
- Time to Cmax (Tmax) of ABBV-8736Time frame: Up to Approximately 113 Days
- Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of ABBV-8736Time frame: Up to Approximately 113 Days
- Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-8736Time frame: Up to Approximately 113 Days
- Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-8736Time frame: Up to Approximately 113 Days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-8736Time frame: Up to Approximately 113 Days
- Clearance (CL) for Intravenous (IV) DosingTime frame: Up to Approximately 113 Days
- Immunogenicity of ABBV-8736 as Determined by Anti-Drug Antibodies (ADAs)Time frame: Up to Approximately 113 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 277377
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.